Keytruda receives FDA approvals in Hodgkin lymphoma indications

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Keytruda (pembrolizumab) has received an expanded label use from FDA as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login